A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
← catalyst calendarNCT05608681 · readout ≤ 134 d
Sponsored by Eupraxia Pharmaceuticals Inc. (industry) · EPRX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
117estimated
Sites
23
Countries
Australia, Canada, Netherlands +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-31 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eosinophilic Esophagitis
Interventions
- Drug: EP-104GI
- Other: Matching vehicle control
Primary outcomes
what the primary-completion date above is the date OFDose Escalation- Incidence of treatment emergent adverse events (TEAEs)
measured 52 weeks
Dose Escalation- Severity of treatment emergent adverse events (TEAEs)
measured 52 weeks
Dose Escalation- Change from baseline in morning serum cortisol levels
measured 52 weeks
Dose Escalation- Plasma concentrations of fluticasone propionate
measured 108 weeks
Dose Escalation- Change from baseline in physical examination results, BMI and weight change.
measured 12 weeks
Randomised Dose Optimization- Change from baseline in EoEHSS grade and stage scored in 3 regions of the esophagus within the injection area (proximal, mid, distal)
measured 24 weeks
Permalink · EPRX's whole pipeline · Catalyst calendar · Every registered study · What changed